Chemours (CC) Cash & Equivalents (2015 - 2025)

Chemours' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $670.0 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 6.03% year-over-year to $670.0 million; the TTM figure through Dec 2025 stood at $670.0 million (down 6.03% YoY), while the FY2025 annual figure was $670.0 million, down 6.03% from the prior year.
• Cash & Equivalents was $670.0 million for Q4 2025 at Chemours, up from $613.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 billion in Q4 2021 to a low of $15.0 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $798.6 million across 5 years, with a median of $834.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 97.65% in 2024, then jumped 3246.67% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $1.5 billion in 2021, then declined by 24.05% to $1.1 billion in 2022, then climbed by 9.17% to $1.2 billion in 2023, then sank by 40.73% to $713.0 million in 2024, then declined by 6.03% to $670.0 million in 2025.
• The last three Cash & Equivalents figures came in at $670.0 million (Q4 2025), $613.0 million (Q3 2025), and $502.0 million (Q2 2025), per Business Quant data.